GlaxoSmithKline Cash and Equivalents vs Total Debt Analysis

GSK Stock  USD 42.99  0.20  0.47%   
Trend analysis of GlaxoSmithKline PLC ADR balance sheet accounts such as Other Current Liabilities of 15 B or Total Current Liabilities of 11.2 B provides information on GlaxoSmithKline PLC's total assets, liabilities, and equity, which is the actual value of GlaxoSmithKline PLC ADR to its prevalent stockholders. By breaking down trends over time using GlaxoSmithKline PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC ADR at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

GlaxoSmithKline PLC Balance Sheet Chart

GlaxoSmithKline PLC Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how GlaxoSmithKline PLC ADR uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, GlaxoSmithKline PLC's Common Stock Shares Outstanding is quite stable compared to the past year. Short Term Investments is expected to rise to about 2.4 B this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.

Total Assets

Total assets refers to the total amount of GlaxoSmithKline PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in GlaxoSmithKline PLC ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on GlaxoSmithKline PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlaxoSmithKline PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although the value of Tax Provision will most likely fall to about 669.3 M.
 2021 2022 2023 2024 (projected)
Interest Expense784M879M775M502.2M
Depreciation And Amortization2.6B2.4B2.3B1.2B

GlaxoSmithKline PLC fundamental ratios Correlations

0.92-0.320.890.50.890.90.770.610.990.370.590.220.16-0.070.950.950.770.970.320.910.710.70.120.940.12
0.92-0.310.830.410.880.980.710.650.90.340.560.020.08-0.150.910.90.810.910.230.870.870.730.030.820.01
-0.32-0.31-0.330.29-0.11-0.36-0.590.0-0.38-0.260.150.240.740.31-0.36-0.21-0.3-0.360.61-0.06-0.380.220.26-0.420.17
0.890.83-0.330.30.890.830.850.450.870.490.520.160.20.050.830.940.740.940.360.870.720.71-0.070.77-0.07
0.50.410.290.30.270.430.10.190.490.20.420.770.560.390.290.350.040.310.560.480.250.330.880.51-0.1
0.890.88-0.110.890.270.830.730.740.840.330.66-0.020.27-0.120.910.970.880.940.430.930.710.92-0.20.730.15
0.90.98-0.360.830.430.830.70.50.890.370.460.080.09-0.090.870.870.740.890.240.820.90.650.080.82-0.08
0.770.71-0.590.850.10.730.70.450.770.550.40.01-0.14-0.10.740.770.780.820.030.670.590.53-0.230.740.0
0.610.650.00.450.190.740.50.450.560.10.73-0.24-0.01-0.370.680.640.740.610.080.720.370.77-0.180.480.35
0.990.9-0.380.870.490.840.890.770.560.310.50.220.12-0.120.940.920.730.950.280.850.70.630.130.970.11
0.370.34-0.260.490.20.330.370.550.10.310.610.320.010.660.330.380.420.410.060.510.330.320.040.22-0.03
0.590.560.150.520.420.660.460.40.730.50.610.210.250.350.570.630.60.580.30.830.320.750.090.350.24
0.220.020.240.160.77-0.020.080.01-0.240.220.320.210.590.680.030.11-0.190.080.570.2-0.120.010.770.25-0.16
0.160.080.740.20.560.270.09-0.14-0.010.120.010.250.590.490.070.23-0.040.130.980.30.050.440.380.09-0.01
-0.07-0.150.310.050.39-0.12-0.09-0.1-0.37-0.120.660.350.680.49-0.18-0.05-0.22-0.090.420.13-0.090.00.42-0.18-0.14
0.950.91-0.360.830.290.910.870.740.680.940.330.570.030.07-0.180.940.870.970.250.870.710.71-0.120.880.27
0.950.9-0.210.940.350.970.870.770.640.920.380.630.110.23-0.050.940.840.980.40.940.70.82-0.080.820.13
0.770.81-0.30.740.040.880.740.780.740.730.420.6-0.19-0.04-0.220.870.840.850.130.80.590.78-0.40.640.29
0.970.91-0.360.940.310.940.890.820.610.950.410.580.080.13-0.090.970.980.850.310.910.750.74-0.110.880.14
0.320.230.610.360.560.430.240.030.080.280.060.30.570.980.420.250.40.130.310.430.180.540.30.260.02
0.910.87-0.060.870.480.930.820.670.720.850.510.830.20.30.130.870.940.80.910.430.650.880.060.720.14
0.710.87-0.380.720.250.710.90.590.370.70.330.32-0.120.05-0.090.710.70.590.750.180.650.55-0.030.65-0.25
0.70.730.220.710.330.920.650.530.770.630.320.750.010.440.00.710.820.780.740.540.880.55-0.140.490.15
0.120.030.26-0.070.88-0.20.08-0.23-0.180.130.040.090.770.380.42-0.12-0.08-0.4-0.110.30.06-0.03-0.140.2-0.22
0.940.82-0.420.770.510.730.820.740.480.970.220.350.250.09-0.180.880.820.640.880.260.720.650.490.20.14
0.120.010.17-0.07-0.10.15-0.080.00.350.11-0.030.24-0.16-0.01-0.140.270.130.290.140.020.14-0.250.15-0.220.14
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets79.7B80.4B79.1B60.1B59.0B32.8B
Short Long Term Debt Total30.5B27.2B24.2B21.0B18.0B11.0B
Other Current Liab755M765M958M2.3B14.3B15.0B
Total Current Liabilities24.1B22.1B23.7B22.8B21.1B11.2B
Total Stockholder Equity12.0B14.6B15.1B10.6B13.3B14.0B
Property Plant And Equipment Net11.3B11.0B10.7B9.6B10.0B7.2B
Net Debt25.8B20.9B19.9B17.3B15.1B8.3B
Accounts Payable14.9B15.8B17.6B16.3B3.7B6.2B
Cash4.7B6.3B4.3B3.7B2.9B2.7B
Non Current Assets Total60.2B60.2B60.4B39.4B40.4B20.9B
Non Currrent Assets Other1.2B1.1B1.8B5.3B634M1.1B
Cash And Short Term Investments4.8B6.4B4.3B7.9B5.2B4.0B
Common Stock Shares Outstanding2.0B2.0B2.0B2.0B4.1B4.3B
Liabilities And Stockholders Equity79.7B80.4B79.1B60.1B59.0B32.8B
Non Current Liabilities Total37.3B37.5B34.1B27.2B25.1B14.3B
Inventory5.9B6.0B5.8B5.1B5.5B3.0B
Other Stockholder Equity5.2B4.9B4.9B5.1B3.2B2.9B
Total Liab61.3B59.6B57.8B50.1B46.2B25.5B
Property Plant And Equipment Gross10.3B11.0B10.7B9.6B20.2B21.2B
Total Current Assets19.5B20.2B18.7B20.8B18.6B11.9B
Short Term Debt6.9B3.7B3.6B4.0B2.8B2.2B
Common Stock1.3B1.3B1.3B1.3B1.3B1.3B
Retained Earnings5.1B6.8B7.9B4.4B7.2B7.6B
Accumulated Other Comprehensive Income641M1.6B642M(48M)1.6B1.7B
Intangible Assets31.0B29.8B30.1B14.3B14.8B11.4B
Other Liab13.7B14.1B13.5B10.2B11.7B14.2B
Long Term Debt22.6B23.4B20.6B17.0B14.2B17.5B
Good Will10.6B10.6B10.6B7.0B6.8B5.3B
Other Current Assets1.6B617M525M7.7B561M533.0M
Property Plant Equipment11.3B11.0B10.7B9.6B8.7B9.7B
Current Deferred Revenue1.4B1.8B1.6B299M222M233.1M
Other Assets5.1B5.3B6.9B6.9B7.9B5.4B
Net Receivables7.1B7.3B8.0B7.1B7.4B6.5B
Net Tangible Assets(30.1B)(25.8B)(25.6B)(10.8B)(12.4B)(13.0B)
Short Long Term Debt6.7B3.5B3.4B3.8B2.7B4.3B
Long Term Debt Total23.6B23.4B20.6B17.0B19.6B20.5B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.02
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.